Drug Information for ENBREL (etanercept) For Subcutaneous Injection (Immunex Corp): INDICATIONS AND USAGE

ENBREL^® is indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in patients with moderately to severely active rheumatoid arthritis. ENBREL^® can be initiated in combination with methotrexate (MTX) or used alone.

ENBREL^® is indicated for reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients ages 2 and older.

ENBREL^® is indicated for reducing signs and symptoms, inhibiting the progression of structural damage of active arthritis, and improving physical function in patients with psoriatic arthritis. ENBREL^® can be used in combination with methotrexate in patients who do not respond adequately to methotrexate alone.

ENBREL^® is indicated for reducing signs and symptoms in patients with active ankylosing spondylitis.

ENBREL^® is indicated for the treatment of adult patients (18 years or older) with chronic moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.